SCHEMBL1325482

SCHEMBL1325482

C=CCNNS(=O)(=O)CC=C

nearest known ligand 0.31

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL756834 0.75 TSHR (0.35) CA12CA1CA2CA9
Hydrogen Sulfide SCHEMBL28249500 0.73 TSHR (0.34) CA12CA1CA2CA9
SCHEMBL7207231 0.73
Fluoride SCHEMBL28144875 0.73 TSHR (0.34) CA12CA1CA2CA9
SCHEMBL28316984 0.73
SCHEMBL6280586 0.71 FAAH (0.40) CA2
SCHEMBL175854 0.71
SCHEMBL253162 0.71
SCHEMBL6310315 0.69
SCHEMBL756566 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107275722-A Battery or fuel cell system 辉光能源公司 2017-10-20 CN disclosed
US-8859590-B2 Inhibitors of BACE1 and methods for treating Alzheimer's disease PURDUE RESEARCH FOUNDATION (US) 2014-10-14 US disclosed
CN-102549836-A Heterogeneous hydrogen-catalyst power system BLACKLIGHT POWER INC 2012-07-04 CN disclosed
US-20110275619-A1 INHIBITORS OF BACE1 AND METHODS FOR TREATING ALZHEIMER'S DISEASE PURDUE RESEARCH FOUNDATION (US) 2011-11-10 US disclosed
US-20050159431-A1 Substituted alkyl uracils and thereof BAYER HEALTHCARE AG (DE) 2005-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275619-A1 INHIBITORS OF BACE1 AND METHODS FOR TREATING ALZHEIMER'S DISEASE BACE1, BACE2, PSEN2 CA12 2907/4885CA1 292/4885CA2 2513/4885
US-20050159431-A1 Substituted alkyl uracils and thereof UNG, UMPS, TYMP CA12 4709/4885CA1 4698/4885CA2 4876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.